The question that matters clinically is whether a given patient is a good candidate, what the right protocol looks like for their specific goals and lab results, and whether they have access to a supervised framework that can catch the small number of patients for whom these compounds are not appropriate before they start rather than after
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
How PlexusDx Supports a More Personalized Approach PlexusDx's precision approach recognizes that diarrhea severity and timeline differ based on genetics, baseline gut health, and individual peptide receptor biology
Nat Rev Mol Cell Biol (2012) 13(4):25162
Pol Arch Med Wewn 1961;31:317320
Here is the video: Here is the YouTube video Link: Here is the screen shot for this video: To get your copy of the book Tailbone Pain Relief Now! go to: www.TailboneBook.com or go to Amazon